Biotech Values

[mcbio]

Now that ACHN has all the cash they need for the time being, they don’t bother to conduct a quarterly CC.

CC would be nice, but I don't think there's much additional color they can add to the story. 1Q11 is the next big event for the company and they need the Phase 2a data for ACH-1625 to be positive. Everything else is just conversation at this point. If those results are positive, then ACHN inches closer to a 1625 partnership IMO (and IMHO most likely with Roche). If the results are negative, then the stock will likely tank and ACHN will focus on ACH-2684 and ACH-2928.